Suresh Kuthuru

List of Publications by Year
in descending order

27 papers	1,356 citations	331670 21 h-index	552781 26 g-index
27 all docs	27 docs citations	27 times ranked	1691 citing authors

#	Article	IF	Citations
1	Metalâ€Organic Framework (MOF) Morphology Control by Design. Chemistry - A European Journal, 2022, 28, .	3.3	29
2	Optimizing Hydrogen Storage in MOFs through Engineering of Crystal Morphology and Control of Crystal Size. Journal of the American Chemical Society, 2021, 143, 10727-10734.	13.7	95
3	Entacapone Polymorphs: Crystal Structures, Dissolution, Permeability, and Stability. Crystal Growth and Design, 2021, 21, 5573-5585.	3.0	13
4	Leveraging Framework Instability: A Journey from Energy Storage to Drug Delivery. Synlett, 2020, 31, 1573-1580.	1.8	4
5	Role of hydrogen bonding in cocrystals and coamorphous solids: indapamide as a case study. CrystEngComm, 2019, 21, 2043-2048.	2.6	20
6	Enhanced Drug Delivery by Dissolution of Amorphous Drug Encapsulated in a Water Unstable Metalâ€“Organic Framework (MOF). Angewandte Chemie - International Edition, 2019, 58, 16790-16794.	13.8	208
7	Enhanced Drug Delivery by Dissolution of Amorphous Drug Encapsulated in a Water Unstable Metalâ€“Organic Framework (MOF). Angewandte Chemie, 2019, 131, 16946-16950.	2.0	28
8	Far-Infrared Spectroscopy as a Probe for Polymorph Discrimination. Journal of Pharmaceutical Sciences, 2019, 108, 1915-1920.	3.3	7
9	Salts and Salt Cocrystals of the Antibacterial Drug Pefloxacin. Crystal Growth and Design, 2018, 18, 2824-2835.	3.0	40
10	Entacapone: Improving Aqueous Solubility, Diffusion Permeability, and Cocrystal Stability with Theophylline. Crystal Growth and Design, 2018, 18, 6061-6069.	3.0	57
11	Curcumin: pharmaceutical solids as a platform to improve solubility and bioavailability. CrystEngComm, 2018, 20, 3277-3296.	2.6	94
12	Curcumin-Artemisinin Coamorphous Solid: Xenograft Model Preclinical Study. Pharmaceutics, 2018, 10, 7.	4.5	33
13	Polymorphism, isostructurality and physicochemical properties of glibenclamide salts. CrystEngComm, 2017, 19, 918-929.	2.6	20
14	Structure and physicochemical characterization of a naproxenâ€“picolinamide cocrystal. Acta Crystallographica Section C, Structural Chemistry, 2017, 73, 168-175.	0.5	28
15	Crystal engineering of a zwitterionic drug to neutral cocrystals: a general solution for floxacins. Chemical Communications, 2016, 52, 12610-12613.	4.1	30
16	Enhanced Bioavailability in the Oxalate Salt of the Anti-Tuberculosis Drug Ethionamide. Crystal Growth and Design, 2016, 16, 1591-1598.	3.0	47
17	Cocrystals and alloys of nitazoxanide: enhanced pharmacokinetics. Chemical Communications, 2016, 52, 4223-4226.	4.1	45
18	Color polymorphs of aldose reductase inhibitor epalrestat: configurational, conformational and synthon differences. Chemical Communications, 2016, 52, 4037-4040.	4.1	26

#	Article	IF	Citations
19	Novel Synthons in Sulfamethizole Cocrystals: Structureâ€“Property Relations and Solubility. Crystal Growth and Design, 2015, 15, 3498-3510.	3.0	58
20	A furosemideâ€“isonicotinamide cocrystal: an investigation of properties and extensive structural disorder. CrystEngComm, 2015, 17, 6707-6715.	2.6	38
21	A novel curcuminâ€“artemisinin coamorphous solid: physical properties and pharmacokinetic profile. RSC Advances, 2014, 4, 58357-58361.	3.6	70
22	Lornoxicam Salts: Crystal Structures, Conformations, and Solubility. Crystal Growth and Design, 2014, 14, 2945-2953.	3.0	38
23	Solubility and Stability Advantage of Aceclofenac Salts. Crystal Growth and Design, 2013, 13, 1590-1601.	3.0	35
24	Andrographolide: Solving Chemical Instability and Poor Solubility by Means of Cocrystals. Chemistry - an Asian Journal, 2013, 8, 3032-3041.	3.3	51
25	Fast dissolving eutectic compositions of curcumin. International Journal of Pharmaceutics, 2012, 439, 63-72.	5.2	110
26	Novel Furosemide Cocrystals and Selection of High Solubility Drug Forms. Journal of Pharmaceutical Sciences, 2012, 101, 664-680.	3.3	132
27	The Role of Secondary Interactions in Centrosymmetry of Charge Transfer Complexes with Nitrated Acceptors. Crystal Growth and Design, 0, , .	3.0	0